MIST (Milestone Pharmaceuticals) Moat Score: 3/10 (As of Jun. 27, 2026)


MIST Milestone Pharmaceuticals Inc MIST
26 GF Score
Price $1.25
! 6 Warning Signs
View Full Analysis

What is Milestone Pharmaceuticals Moat Score?

Milestone Pharmaceuticals MIST -0.80% 26 Moat Score is 3 as of Jun. 27, 2026. GuruFocus rates MIST with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 1,404 Biotechnology companies, Milestone Pharmaceuticals ranks better than 75.5% on this metric.

Milestone Pharmaceuticals has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Milestone Pharmaceuticals has No Moat: Milestone Pharmaceuticals Inc has limited competitive advantages in the pharmaceutical sector. The company lacks significant market share, brand strength, and intellectual property, facing substantial competition and regulatory challenges without strong customer loyalty or switching costs.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Milestone Pharmaceuticals might have No Moat - Very weak/transient advantages.

Milestone Pharmaceuticals  (NAS:MIST) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Milestone Pharmaceuticals Moat Score Related Terms

MIST vs TLSA, DTIL, OKUR: Moat Score Comparison

For the Biotechnology subindustry, Milestone Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Milestone Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Milestone Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Milestone Pharmaceuticals's Moat Score falls into.


MIST
26GF Score
Milestone Pharmaceuticals Inc MIST
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Milestone Pharmaceuticals (MIST) has a Moat Score of 3 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Milestone Pharmaceuticals ranks #344 out of 1404 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Milestone Pharmaceuticals' Moat Score too high?
Milestone Pharmaceuticals' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Milestone Pharmaceuticals' value of 3 is 50% above this industry median. Based on the distribution chart, Milestone Pharmaceuticals ranks #344 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Milestone Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Milestone Pharmaceuticals' Moat Score compare to TLSA and DTIL?
According to the Biotechnology industry distribution chart, Milestone Pharmaceuticals ranks #344 out of 1404 companies for Moat Score. This places Milestone Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Milestone Pharmaceuticals' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Milestone Pharmaceuticals's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Milestone Pharmaceuticals's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Milestone Pharmaceuticals stock overvalued right now?
Milestone Pharmaceuticals (MIST) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Milestone Pharmaceuticals' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Milestone Pharmaceuticals (MIST), the current Moat Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Milestone Pharmaceuticals Business Description

Address 1111 Dr. Frederik-Phillips Boulevard, Suite 420, Montreal, QC, CAN, H4M 2X6
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
26GF Score

Get the complete analysis for MIST

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.25
Price